Sleep Disturbance and Bipolar Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00993850
Recruitment Status : Completed
First Posted : October 14, 2009
Last Update Posted : April 16, 2013
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
Allison Harvey, National Institute of Mental Health (NIMH)

Brief Summary:
The study aims to evaluate a psychological intervention for individuals who suffer from sleep disturbance and bipolar disorder. We are hoping that this treatment will: (1) improve the quality of life of individuals with bipolar disorder who are suffering from sleep disturbance and (2) reduce the risk of, or help prevent, episodes.

Condition or disease Intervention/treatment Phase
Bipolar Disorder Dyssomnias Behavioral: Cognitive behavioral therapy for insomnia Other: Bipolar education Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 52 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: A Psychological Intervention for Individuals Who Suffer From Sleep Disturbance and Bipolar Disorder
Study Start Date : October 2009
Actual Primary Completion Date : April 2012
Actual Study Completion Date : July 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Bipolar disorder education
Other: Bipolar education

Cognitive behavioral therapy
Cognitive behavioral therapy for insomnia
Behavioral: Cognitive behavioral therapy for insomnia
Attending 6-10 treatment sessions in one of our interview rooms. The sessions will be offered on a weekly basis. Each session takes approximately 50 minutes.

Primary Outcome Measures :
  1. Improvements in sleep, emotional functioning and quality of life [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Bipolar disorder patients with sleep disturbance

  1. Meeting Diagnostic and Statistical Manual of Mental Disorders, 4th Text Revision (DSM-IV-TR; APA, 2000) diagnostic criteria for bipolar disorder type 1 (established with the SCID: Structured Clinical Interview for DSM-IV).
  2. Being inter-episode throughout the experiment as defined by cutoffs widely used in previous research. On the basis that a drug-free group would likely be unfeasible and unrepresentative, participants will not be excluded on the basis of medications prescribed for bipolar disorder. Comorbidity will be allowed as long as bipolar disorder is the primary diagnosis. However, it is necessary to assess comorbidity for reporting purposes.
  3. Participants who have a history of bipolar 1 or suicidal ideation must be under the care of a psychiatrist.
  4. Experience distress related to significant sleep disturbance.

Exclusion Criteria:

  1. Presence of an active and progressive physical illness (e.g., congestive heart failure, cancer, COPD) or neurological degenerative diseases (e.g., dementia, multiple sclerosis) directly related to the onset and course of insomnia;
  2. Alcohol or drug abuse (except nicotine) within the past year
  3. Active posttraumatic stress disorder
  4. Evidence of sleep apnea, restless legs syndrome or periodic limb movements during sleep, or a circadian-based sleep disorder (e.g., delayed or advanced sleep phase syndrome)
  5. Patients who pose a current suicidal risk or homicidal risk (assessed by treating psychiatrist) or who have made a suicide attempt within the past 6 months.
  6. Pharmacotherapy for sleep defined as the benzodiazepine and non-benzodiazepine hypnotics that operate via the GABA A receptor complex and are FDA approved for the treatment of insomnia, selective melatonin agonists, benzodiazepine anxiolytics and over the counter medications with proven efficacy such as melatonin or herbs such as St. Johns wort.
  7. Use of certain medications known to alter sleep (e.g., steroids, theophylline, propranolol, antihistamines that cause drowsiness).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00993850

United States, California
University of California at Berkeley
Berkeley, California, United States, 94720-1650
Sponsors and Collaborators
University of California, Berkeley
National Institute of Mental Health (NIMH)

Responsible Party: Allison Harvey, Professor of Clinical Psychology, National Institute of Mental Health (NIMH) Identifier: NCT00993850     History of Changes
Other Study ID Numbers: R34MH080958 ( U.S. NIH Grant/Contract )
R34MH080958 ( U.S. NIH Grant/Contract )
First Posted: October 14, 2009    Key Record Dates
Last Update Posted: April 16, 2013
Last Verified: April 2013

Keywords provided by Allison Harvey, National Institute of Mental Health (NIMH):
Bipolar disorder
Sleep disturbance
Cognitive behavioral therapy

Additional relevant MeSH terms:
Bipolar Disorder
Sleep Wake Disorders
Pathologic Processes
Bipolar and Related Disorders
Mental Disorders
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms